ImmunoCellular Therapeutics, Ltd. ((NYSE: IMUC) announced today that it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments Momentum Movers

Feuerstein Takes Shot at ImmunoCellular Therapeutics (IMUC) After Shares JumpDecember 13, 2017 4:30 PM ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology ProgramDecember 13, 2017 4:05 PM